Related Experiment Video

Updated: Aug 12, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Histone deacetylase inhibitors and cancer therapy

N B La Thangue1

  • 1University of Glasgow, Glasgow, G12 8QQ, UK. N.LaThangue@bio.gla.ac.uk

Journal of Chemotherapy (Florence, Italy)
|February 4, 2005
PubMed

Insights

Histone deacetylase (HDAC) inhibitors represent a targeted cancer therapy approach. These drugs induce tumor cell death by modulating epigenetic control, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Cancer treatment is shifting towards targeted therapies.
  • Epigenetic regulation, particularly involving histone deacetylases (HDACs), is crucial in cancer.
  • HDACs play a role in cell growth and gene transcription.

Purpose of the Study:

  • To review histone deacetylase (HDAC) inhibitors.
  • To discuss their clinical development status.
  • To evaluate their potential in cancer treatment.

Main Methods:

  • Literature review of HDAC inhibitors.
  • Analysis of clinical trial data for HDAC inhibitors.
  • Assessment of HDAC inhibitor mechanisms in cancer.

Main Results:

  • HDAC inhibitors are a class of targeted cancer drugs.
  • Inhibition of HDAC activity leads to tumor cell apoptosis.
  • Clinical development of HDAC inhibitors is ongoing.

Conclusions:

  • HDAC inhibitors show promise as a cancer therapy.
  • Targeting epigenetic mechanisms offers a novel therapeutic avenue.
  • Further clinical development is warranted for HDAC inhibitors in oncology.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...